Literature DB >> 3899668

Acute haemodynamic effects of felodipine in congestive heart failure.

H Emanuelsson, A Hjalmarson, S Holmberg, F Waagstein.   

Abstract

The haemodynamic effects of felodipine 0.1 mg/kg p.o., a new arteriolar dilator, were studied in 7 patients with severe congestive heart failure of NYHA Class IV (Group A) and in 3 patients in Class II-III (Group B). In Group A, measurements were made before and 1 and 4 h after felodipine administration. There was a substantial fall in systemic arterial pressure, which was not associated with a compensatory tachycardia. In fact, there was a fall in heart rate from 92 to 82 beats/min 1 h after drug administration. The pulmonary capillary wedge pressure was reduced from 22 to 14 mm Hg and the cardiac index and stroke volume index rose significantly. Consequently, there was a marked reduction in systemic vascular resistance. In Group B measurements were performed at rest and during exercise before and 1 h after felodipine. The pulmonary wedge capillary pressure during exercise was lower than in the control situation. Coronary sinus flow was increased and there was a pronounced fall in coronary vascular resistance. The results would suggest that felodipine, by virtue of its ventricular unloading potency, might be a valuable drug in the treatment of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899668     DOI: 10.1007/bf00544056

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Electrophysiological effects of felodipine.

Authors:  M Been; P W Macfarlane; W S Hillis
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 2.  Coronary vascular responses to vasodilator drugs.

Authors:  R E Goldstein
Journal:  Prog Cardiovasc Dis       Date:  1982 May-Jun       Impact factor: 8.194

3.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

4.  Alterations in the baroreceptor reflex in conscious dogs with heart failure.

Authors:  C B Higgins; S F Vatner; D L Eckberg; E Braunwald
Journal:  J Clin Invest       Date:  1972-04       Impact factor: 14.808

5.  Angiotensin converting enzyme inhibition in patients with congestive heart failure.

Authors:  H Gavras; D P Faxon; J Berkoben; H R Brunner; T J Ryan
Journal:  Circulation       Date:  1978-11       Impact factor: 29.690

6.  Effects of felodipine on systemic and coronary haemodynamics in patients with angina pectoris.

Authors:  H Emanuelsson; A Hjalmarson; S Holmberg; F Waagstein
Journal:  Eur Heart J       Date:  1984-04       Impact factor: 29.983

7.  Acute diuretic/natriuretic properties of felodipine in man.

Authors:  B Edgar; B Bengtsson; D Elmfeldt; P Lundborg; G Nyberg; S Raner; O Rönn
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.

Authors:  A L Muir; C G Wathen; W J Hannan
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  Haemodynamic effects of a new vasodilator drug, felodipine, in healthy subjects.

Authors:  G Johnsson; G Murray; A Tweddel; I Hutton
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Felodipine. A calcium-inhibiting vasodilator in refractory hypertension.

Authors:  O K Andersson; G Granérus; T Hedner
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more
  9 in total

Review 1.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

2.  Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress.

Authors:  E Kassis; O Amtorp; S Waldorff; P Fritz-Hansen
Journal:  Br Heart J       Date:  1987-11

Review 3.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

Review 4.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

5.  Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.

Authors:  L B Tan; R G Murray; W A Littler
Journal:  Br Heart J       Date:  1987-08

Review 6.  Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.

Authors:  W C Little; C P Cheng; L Elvelin; M Nordlander
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

7.  Hemodynamic effects of felodipine in congestive heart failure.

Authors:  G Binetti; S Pancaldi; N Giovanelli; S Negroni; R M Ferretti; A Branzi; S Specchia; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

8.  Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.

Authors:  W A Littler; D J Sheridan
Journal:  Br Heart J       Date:  1995-05

9.  Central and peripheral haemodynamic responses to felodipine in congestive heart failure.

Authors:  S Capewell; C G Wathen; A L Muir
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.